Xenon Pharmaceuticals (XENE) Tops Q3 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Xenon Pharmaceuticals (XENE) Tops Q3 EPS by 15c

Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 5, 2019 4:01 PM EST

In Addition to Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy, Company Advances Epilepsy Programs and Anticipates Initiating Pediatric Clinical Trials in KCNQ2 (XEN496) and SCN8A (XEN901) Developmental and Epileptic Encephalopathies in 2020 

XEN007 Phase 2 Proof-Of-Concept, Physician-Led Study Initiated in Pediatric Patients with  Treatment-Resistant Childhood Absence Epilepsy

Conference Call at 4:30 pm ET Today

BURNABY, British Columbia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:... More